[1]
|
J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al., “Secondary Prevention of Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study (PRO Spective Pioglit Azone Clinical Trial in MacroVascular Events): A Randomised Controlled Trial,” Lancet, Vol. 366, No. 9493, 2005, pp. 1279-1289. http://dx.doi.org/10.1016/S0140-6736(05)67528-9
|
[2]
|
A. Keech, R. J. Simes, P. Barter, et al., “Effects of Long-Term Fenofibrate Therapy on Cardiovascular Events in 9795 People with Type 2 Diabetes Mellitus (the FIELD Study): Randomised Controlled Trial,” Lancet, Vol. 366, No. 9500, 2005, pp. 1849-1861. http://dx.doi.org/10.1016/S0140-6736(05)67667-2
|
[3]
|
ACCORD Study Group, H. N. Ginsberg, M. B. Elam, L. C. Lovato, et al., “Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus,” New England Journal of Medicine, Vol. 362, No. 17, 2010, pp. 1563-1574. http://dx.doi.org/10.1056/NEJMoa1001282
|
[4]
|
M. Jun, C. Foote, J. Lv, et al., “Effects of Fibrates on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis,” Lancet, Vol. 375 No. 9729, 2010, pp. 1875-1884. http://dx.doi.org/10.1016/S0140-6736(10)60656-3
|
[5]
|
S. Kasai, T. Inoue, H. Yoshitomi, et al., “Antidiabetic and Hypolipidemic Effects of a Novel Dual Peroxisome Proliferator-Activated Receptor (PPAR) α/γ Agonist, E3030, in db/db Mice and Beagle Dogs,” Journal of Pharmacological Sciences, Vol. 108, No. 1, 2008, pp. 40-48. http://dx.doi.org/10.1254/jphs.FP0072346
|
[6]
|
Food and Drug Administration, “Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers,” Draft Guidance, USDHHS, FDA, CDER, CBER, 2002.
|
[7]
|
T. Hashimoto, H. Kasai, M. Yamada, et al., “Statistical Assessment of Linear Pharmacokinetics in Clinical Pharmacological Studies,” Xenobiotic Metabolism and Disposition, Vol. 16, No. 3, 2001, pp. 244-252.
|
[8]
|
Food and Drug Administration, “Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies,” FDA, CDER, 2002.
|
[9]
|
T. M. O’Moore-Sullivan and J. B. Prins, “Thiazolidinediones and Type 2 Diabetes: New Drugs for an Old Disease,” Medical Journal of Australia, Vol. 176, No. 8, 2002, pp. 381-386.
|
[10]
|
R. R. Henry, A. M. Lincoff, S. Mudaliar, et al., “Effect of the Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonist Aleglitazar on Risk of Cardiovascular Disease in Patients with Type 2 Diabetes (SYNCHRONY): A Phase II, Randomised, Dose-Ranging Study,” Lancet, Vol. 374, No. 9684, 2009, pp. 126-135. http://dx.doi.org/10.1016/S0140-6736(09)60870-9
|
[11]
|
W. C. Roberts, “Safety of Fenofibrate—US and Worldwide Experience,” Cardiology, Vol. 76, No. 3, 1989, pp. 169-179. http://dx.doi.org/10.1159/000174488
|
[12]
|
G. F. Blane, “Comparative Toxicity and Safety Profile of Fenofibrate and Other Fibric Acid Derivatives,” American Journal of Medicine, Vol. 83, No. Suppl. 5B, 1987, pp. 26-36. http://dx.doi.org/10.1016/0002-9343(87)90868-0
|
[13]
|
G. F. Blane, “Review of European Clinical Experience with Fenofibrate,” Cardiology, Vol. 76, No. Suppl. 1, 1989, pp. 1-13. http://dx.doi.org/10.1159/000174541
|
[14]
|
B. Davies and T. Morris, “Physiological Parameters in Laboratory Animals and Humans,” Pharmaceutical Research, Vol. 10, No. 7, 1993, pp. 1093-1095. http://dx.doi.org/10.1023/A:1018943613122
|